🟢 Tscan Therapeutics is trading 7% up in pre-market with broader risk-on sentiment

Tscan Therapeutics is trading at $0.33, up +7.02%, with broader pre-market risk-on sentiment the most likely explanation for the move.

• Major U.S. indices are up more than 0.5%; shares closed at $0.31 on September 18, 2026.
• No new company-specific announcement was identified for September 21; latest material developments remain the September 2 strategic reorganization and September 11 retention program.
• No confirmed earnings, FDA, partnership, or analyst catalyst was identified.